Copyright
©The Author(s) 2019.
World J Gastroenterol. Aug 14, 2019; 25(30): 4235-4245
Published online Aug 14, 2019. doi: 10.3748/wjg.v25.i30.4235
Published online Aug 14, 2019. doi: 10.3748/wjg.v25.i30.4235
Table 1 Characteristics of mild Crohn’s patients at diagnosis, n (%)
Variables | Mild case (n = 29) | Moderate or severe case (n = 58) | P value |
Age at diagnosis, yr | 10.0 (4.2) | 11.6 (3.3) | 0.06 |
Male % | 15 (51.7) | 29 (52.7) | 0.93 |
Paris Location at diagnosis | |||
Lower 1/3 of ileum +/- base of cecum | 6 (20.7) | 7 (12.1) | 0.29 |
Colon only | 9 (31.0) | 7 (12.1) | 0.03 |
Ileum and colon | 13 (44.8) | 41 (70.7) | 0.02 |
Upper GI proximal to ligament of treitz | 7 (24.1) | 25 (43.1) | 0.08 |
Distal to ligament of treitz to proximal ileum | 1 (3.5) | 2 (3.5) | 1.00 |
Disease behavior at diagnosis | |||
Inflammatory (non-stricturing, non-penetrating) | 28 (96.6) | 51 (87.9) | 0.19 |
Stricturing | 0 (0) | 3 (5.2) | 0.21 |
Penetrating | 0 (0) | 1 (1.7) | 0.48 |
Perianal | 3 (10.3) | 12 (20.7) | 0.23 |
Table 2 Outcome of mild disease patients after the first 2 years of study entry
n (%) | |
Starting immunomodulator | 8 (27.6) |
Starting biologic | 0 |
Starting immunomodulator and biologic | 0 |
Surgery | 0 |
Continued on minimal therapy | 21 (72.4) |
Table 3 Predictors of escalation to immunomodulators among mild Crohn’s patients
Univariate | P value | |
Hazard ratio (95%CI) | ||
Age at diagnosis | 1.24 (0.97-1.59) | 0.09 |
Gender (female vs male) | 0.67 (0.15-3.00) | 0.60 |
Paris location at diagnosis | ||
Lower 1/3 of ileum +/- base of cecum | 1.29 (0.30-5.66) | 0.73 |
Colon only | 0.96 (0.19-4.99) | 0.96 |
Ileum and colon | 0.50 (0.10-2.53) | 0.40 |
Upper GI proximal to Ligament of Treitz | 1.00 (0.19-5.17) | 1.00 |
Distal to Ligament of Treitz to proximal ileum | 5.46 (0.61-49.27) | 0.13 |
Any steroids in the first 2 yr | 1.26 (0.30-5.35) | 0.75 |
Any steroids after the first 2 yr | 12.1 (1.4-102.7) | 0.02 |
Complications | 5.6 (1.3-24.9) | 0.02 |
Table 4 Detailed outcomes of 29 patients on no immunosuppressive therapy for mild Crohn’s disease
Year (age) of diagnosis | Duration of follow-up after initial 2 yr of treatment (mo) | Followup colonoscopy histology findings | Medications | Outcome/ complications |
2002 (10 yr) | 111 | 2007-normal colonoscopy | 5-ASA (Asacol), prednisone | Escalation to 6MP(age 20) Surgery for ileal stricture (age 22) |
2004 (12 yr) | 49 | 2009-Noncaseating granulomas in TI and throughout colon. | 5-ASA (Pentasa, Lialda) | Stayed on ASA, no escalation |
2001 (9 yr) | 32 | Not done | 5-ASA, prednisone | Stayed on ASA, no prednisone after induction, no escalation |
2002 (10 yr) | 131 | 2009- chronic active ileitis with ulceration | 5-ASA (Pentasa, Lialda) | 2015-escalation to mercaptopurine, then adalimumab |
2003 (10 yr) | 66 | 2010-severely active ileitis | 5-ASA (Pentasa), 3 courses of prednisone over 3 years | 2012-began mercaptopurine |
2005 (13 yr) | 15 | Not done | 5-ASA (Asacol) | Ileal phlegmon, treated with antibiotics and subsequent mercaptopurine |
2010 (16 yr) | 43 | 2014-nonnecrotizing granuloma throughout the colon | 5-ASA (Asacol) | Stayed on ASA, no escalation. |
2010 (16 yr) | 1 | Not done | 5-ASA (Asacol), hydrocortisone | Stayed on ASA, no steroid after initial induction |
2008 (14 yr) | 63 | 2010-mild active ileitis colitis in ascending and sigmoid colon | 5-ASA (Asacol), metronidazole | Stayed on ASA, no escalation |
2012 (17 yr) | 7 | 2014-nonnecrotizing granulomas in left colon | 5-ASA (Pentasa) | Escalation to mercaptopurine, then adalimumab |
2008 (14 yr) | 65 | 2012-normal ileum, chronic active colitis 2016-normal colonoscopy | 5-ASA (Pentasa), budesonide | No escalation |
2008 (13 yr) | 47 | 2014-mild active colitis, in ascending, granuloma in ileum | 5-ASA (Pentasa), metronidazole | 6MP initiated |
2007 (12 yr) | 71 | 2016-Inactive colitis at IC valve | 5-ASA (Asacol) | Ileal stricture in 2016, no surgery yet |
2008 (13 yr) | 21 | 2009-active colitis in cecum, inactive in remainder of colon | 5-ASA (Pentasa, Lialda) | Discontinued all therapy, never hospitalized |
2005 (10 yr) | 14 | None prior to escalation | 5-ASA (Pentasa), metronidazole | 6MP, then infliximab |
2010 (15 yr) | 6 | None | 5-ASA (Pentasa), prednisone induction | No escalation |
2005 (9 yr) | 85 | 2013-focal mild ileitis | 5-ASA (Pentasa), metronidazole | No escalation |
2000 (4 yr) | 1 | Not done | Sulfasalazine, flagyl | Begun infliximab for colonic and perianal disease |
2002 (12 yr) | 38 | 2012-normal colonoscopy | 5-ASA (mesalamine), prednisone | No escalation |
2006 (9 yr) | 87 | 2016-chronic active colitis, non- necrotizing granuloma in transverse colon | 5-ASA (Pentasa), two courses of steroids in first two years | No escalation |
2002 (4 yr) | 136 | 2010-mild active colitis | Sulfasalazine, budesonide | No escalation |
2001 (3 yr) | 100 | Not done | Sulfasalazine, budesonide | No escalation |
2003 (5 yr) | 118 | 2012-focal moderately active colitis | Sulfasalazine, prednisone | No escalation |
2009 (10 yr) | 41 | 2014-focal acute inflammation | 5ASA (Asacol), Budesonide | No escalation |
2005 (7 yr) | 99 | 2014-mildly active colitis | Pentasa | No escalation |
2007 (6 yr) | 97 | 2013- chronic inactive colitis | Pentasa, Sulfasalazine | No escalation |
2012 (10 yr) | 16 | 2013-mild active colitis with granulomata | Asacol, prednisone induction | No escalation |
2008 (3 yr) | 54 | Not done | Sulfasalazine, probiotics | No escalation |
2010 (3 yr) | 11 | 2012-chronic moderately active colitis | Sulfasalazine, prednisone induction | No escalation |
- Citation: Sharma Y, Bousvaros A, Liu E, Bender Stern J. Natural history of children with mild Crohn’s disease. World J Gastroenterol 2019; 25(30): 4235-4245
- URL: https://www.wjgnet.com/1007-9327/full/v25/i30/4235.htm
- DOI: https://dx.doi.org/10.3748/wjg.v25.i30.4235